# Novartis, Amgen and Eli Lilly are in late-stage trials to test whether drugs that cut Lp(a) can protect people from heart attacks.

*biotech · news · 2026-04-27 · CNBC*

## Key points

- Novartis, Amgen, and Lilly are in late-stage trials testing drugs to lower Lp(a) cholesterol.
- Novartis' Phase 3 readout of pelacarsen, expected mid-2024, will be the first clinical outcome data.
- All three companies proved their drugs cut Lp(a) by over 80%, but clinical benefit remains unproven.
- Less than 1% of U.S. adults were tested for Lp(a) in 2024, despite new screening recommendations.
- Lilly is developing both a daily pill and a gene-editing treatment to target Lp(a) reduction.

**Companies:** Novartis, Amgen, Eli Lilly
**Countries:** United States, Switzerland

[Read the full story on CNBC](https://www.cnbc.com/2026/04/27/lpa-drugs-from-novartis-amgen-and-eli-lilly-aim-to-prevent-heart-attacks.html)

---

Canonical: https://newsio.io/n/bff83ab8-d1b2-47ad-93eb-b46df59018bd/novartis-amgen-and-eli-lilly-are-in-late-stage-trials-to-test-whether-drugs-that
Summarized by Newsio from CNBC. https://newsio.io/how-it-works